Hanall Biopharma Co., Ltd. Statistics
Want to see KR:009420 full AI Analyst Report?
Hanall Biopharma Co., Ltd. (009420) Stock Statistics & Valuation Metrics
Total Valuation
Hanall Biopharma Co., Ltd. has a market cap or net worth of KRW 2.72T. The enterprise value is KRW 2.26T.
- Market Cap
- KRW 2.72T
- Enterprise Value
- KRW 2.26T
Share Statistics
Hanall Biopharma Co., Ltd. has 52,240,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 52,240,640
- Owned by Insiders
- ―
- Owned by Institutions
- 5.13%
Financial Efficiency
Hanall Biopharma Co., Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -0.74%.
- Return on Equity (ROE)
- -0.03
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -0.74%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 492.65M
- Profits Per Employee
- -17.65M
- Employee Count
- 315
- Asset Turnover
- 0.69
- Inventory Turnover
- 2.00
Valuation Ratios
The current PE Ratio of Hanall Biopharma Co., Ltd. is -122.17. Hanall Biopharma Co., Ltd.’s PEG ratio is -0.17.
- PE Ratio
- -122.17
- PS Ratio
- 16.44
- PB Ratio
- 17.74
- Price to FCF
- -340.32
- Price to Operating Cash Flow
- -395.32
- PEG Ratio
- -0.17
Income Statement
In the last 12 months, Hanall Biopharma Co., Ltd. had revenue of 155.18B and earned -5.56B in profits. Earnings per share was -111.55.
- Revenue
- 155.18B
- Gross Profit
- 79.10B
- Operating Income
- -1.61B
- Pretax Income
- -6.18B
- Net Income
- -5.56B
- EBITDA
- 1.94B
- Earnings Per Share (EPS)
- -111.55
Cash Flow
In the last 12 months, operating cash flow was -6.91B and capital expenditures -904.45M, giving a free cash flow of -7.82B billion.
- Operating Cash Flow
- -6.91B
- Free Cash Flow
- -7.82B
- Free Cash Flow per Share
- -149.61
Dividends & Yields
Hanall Biopharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.29%
- Earnings Yield
- -0.81%
Stock Price Statistics
- Beta
- 0.48
- 52-Week Price Change
- 15.84%
- 50-Day Moving Average
- 44377.00
- 200-Day Moving Average
- 51430.75
- Relative Strength Index (RSI)
- 66.58
- Average Volume (3m)
- 267.36K
Important Dates
Hanall Biopharma Co., Ltd. upcoming earnings date is Jan 20, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Jan 20, 2027
- Ex-Dividend Date
- ―
Financial Position
Hanall Biopharma Co., Ltd. as a current ratio of 1.91, with Debt / Equity ratio of 19.74%
- Current Ratio
- 1.91
- Quick Ratio
- 1.05
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 3.70
- Interest Coverage Ratio
- -11.31
Taxes
In the past 12 months, Hanall Biopharma Co., Ltd. has paid -621.61M in taxes.
- Income Tax
- -621.61M
- Effective Tax Rate
- 0.10
Enterprise Valuation
Hanall Biopharma Co., Ltd. EV to EBITDA ratio is -208.72, with an EV/FCF ratio of -342.44.
- EV to Sales
- 16.55
- EV to EBITDA
- -208.72
- EV to Free Cash Flow
- -342.44
- EV to Operating Cash Flow
- -387.26
Balance Sheet
Hanall Biopharma Co., Ltd. has KRW 23.32B in cash and marketable securities with KRW 39.90B in debt, giving a net cash position of -KRW 16.58B billion.
- Cash & Marketable Securities
- KRW 23.32B
- Total Debt
- KRW 39.90B
- Net Cash
- -KRW 16.58B
- Net Cash Per Share
- -KRW 317.36
- Tangible Book Value Per Share
- KRW 1,867.92
Margins
Gross margin is 51.29%, with operating margin of 3.00%, and net profit margin of -13.69%.
- Gross Margin
- 51.29%
- Operating Margin
- 3.00%
- Pretax Margin
- -15.50%
- Net Profit Margin
- -13.69%
- EBITDA Margin
- -7.93%
- EBIT Margin
- -9.88%
Analyst Forecast
The average price target for Hanall Biopharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 5.00%
- EPS Growth Forecast
- -1058.77%
Scores
- Smart Score
- ―
- AI Score
- 52

